RSS Basilea Collaborates With Innoviva Specialty Therapeutics For Commercialization Of Zevtera In The US

Currently reading:
 RSS Basilea Collaborates With Innoviva Specialty Therapeutics For Commercialization Of Zevtera In The US

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
6,209
Likes
1,916
Credits
32,769©
Cash
0$
Basilea Pharmaceutica has established an exclusive distribution and licensing agreement with Innoviva Specialty Therapeutics, a division of Innoviva (INVA), to market its hospital anti-MRSA antibiotic, Zevtera, also known as ceftobiprole, within the United States.

Under this agreement, Basilea will receive an initial payment of $4 million, alongside tiered royalties from net sales, ranging from the high teens to mid-twenties percentage. Furthermore, Basilea stands to earn up to $223 million in sales milestones. Innoviva Specialty Therapeutics will also source its Zevtera product supply directly from Basilea.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips
Top Bottom